Basic Information
| LncRNA/CircRNA Name | SNHG5 |
| Synonyms | SNHG5, C6orf160, LINC00044, NCRNA00044, U50HG, bA33E24.2 |
| Region | GRCh38_6:85660950-85678736 |
| Ensemble | ENSG00000203875 |
| Refseq | NR_003038 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | Western blot, in vitro knockdown, Luciferase reporter assay, RNAi etc. |
| Sample | cell line (PC9, A549, HEK-293T), lung adenocarcinoma tissues |
| Expression Pattern | down-regulated |
| Function Description | Overexpression of SNHG5 suppressed the expression of miR-377, while the knockdown of SNHG5 increased the miR-377 expression. MiR-377 expression was significantly upregulated in LAD specimens with acquired gefitinib resistance and was negatively correlated with SNHG5 expression. In addition, CASP1 was predicted as a downstream target of miR-377.Knockdown of CASP1 in SNHG5-overexpression PC9GR cells abolished their gefitinib resistance. |
| Pubmed ID | 29592872 |
| Year | 2018 |
| Title | The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targeting miR-377/CASP1 axis. |
External Links
| Links for SNHG5 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |